A new drug that appears to slow early Alzheimer’s disease is coming to the market.
The Food and Drug Administration on Friday approved lecanemab, which will be marketed as Leqembi, for public use.
The decision comes after data published in The New England Journal of Medicine in November showed that people who took the drug experienced “moderately less decline on measures of cognition and function.”
